Last updated on March 2019

Regorafenib Post-marketing Surveillance in Japan

Brief description of study

The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice

Detailed Study Description

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for gastrointestinal stromal tumors progressed after cancer chemotherapy.

A total of 135 patients are to be enrolled and assessed in 6 months standard observational period. At 12 months and 24 months after the first administration of Regorafenib for confirmation of efficacy information including treatment duration and survival status of the patient.

Clinical Study Identifier: NCT01933958

Contact Investigators or Research Sites near you

Start Over

Bayer Clinical Trials Contact

Multiple Locations, Japan
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.